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Abstract: Prostate cancer (PCa) has become the most common cancer among males in Europe and the
USA. Adoptive immunotherapy appears a promising strategy to control the advanced stages of the
disease by specifically targeting the tumor, in particular through chimeric antigen receptor T (CAR-T)
cell therapy. Despite the advancements of CAR-T technology in the treatment of hematological
malignancies, solid tumors still represent a challenge. To overcome current limits, other cellular
effectors than T lymphocytes are under study as possible candidates for CAR-engineered cancer
immunotherapy. A novel approach involves the NK-92 cell line, which mediates strong cytotoxic
responses against a variety of tumor cells but has no effect on non-malignant healthy counterparts.
Here, we report a novel therapeutic approach against PCa based on engineering of NK-92 cells with a
CAR recognizing the human prostate-specific membrane antigen (PSMA), which is overexpressed in
prostatic neoplastic cells. More importantly, the potential utility of NK-92/CAR cells to treat PCa has
not yet been explored. Upon CAR transduction, NK-92/CAR cells acquired high and specific lytic
activity against PSMA-expressing prostate cancer cells in vitro, and also underwent degranulation and
produced high levels of IFN-γ in response to antigen recognition. Lethal irradiation of the effectors,
a safety measure requested for the clinical application of retargeted NK-92 cells, fully abrogated
replication but did not impact on phenotype and short-term functionality. PSMA-specific recognition
and antitumor activity were retained in vivo, as adoptive transfer of irradiated NK-92/CAR cells
in prostate cancer-bearing mice restrained tumor growth and improved survival. Anti-PSMA
CAR-modified NK-92 cells represent a universal, off-the-shelf, renewable, and cost-effective product
endowed with relevant potentialities as a therapeutic approach for PCa immunotherapy.
Keywords: cancer immunotherapy; prostate cancer; CAR; PSMA; NK-92 cell line
1. Introduction
Remarkable therapeutic responses have been recently achieved with T cells expressing chimeric
antigen receptors (CARs) to tumor antigens, especially in patients with lymphoid malignancies [1–4].
Although these data highlight the potentiality of immune cells to translate into powerful therapeutic
agents, nonetheless successes in the hematological setting have yet to find full validation in solid
tumors. Moreover, apart from a relevant association of CAR-T cell treatment with adverse events
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including a potentially fatal “cytokine release syndrome”, the logistics and costs of this approach pose
significant challenges to make it available to a wide number of patients.
An increasing number of investigators believe that natural killer (NK) cells obtained from the
peripheral blood of either the patient (autologous) or a healthy donor (allogeneic), might represent
safer effectors for targeted cancer therapy than T cells. Additionally, the availability of continuously
expanding NK cell lines provides a potentially unlimited source of effector cells, which can be
investigated for genetic engineering [5–7], but also hold the potential for the development as
standardized off-the-shelf therapeutics for adoptive cancer immunotherapy (ACT). Among such
NK cell lines, NK-92 cells are those that have been most thoroughly investigated and have already
reached the testing phase in the clinical setting [8–11]. In this scenario, CAR-engineered NK-92 cells
could offer a valid and cost-effective alternative to primary CAR NK or T cells, in particular in those
cases where a suitable donor is not available or the sophisticated infrastructures needed for cell isolation,
expansion, and genetic modification are lacking. In this regard, the methodologies for continuous
good manufacturing practice (GMP)-compliant expansion from an established master cell bank have
been validated in the framework of early phase clinical trials with unmodified NK-92 cells, and can
be easily adapted for large-scale production in centralized facilities [8,12]. This provides a further
advantage that may be readily extended to CAR-engineered NK-92 variants. Indeed, in contrast to
CAR approaches based on autologous or donor-derived primary cells, the genetic modification of
NK-92 cells is not performed in a patient-individual setting under tight time constraints. Instead,
a molecularly and functionally well-characterized cell product can be established that is endowed
with a particular target specificity, and is continuously available independently from the time point of
therapeutic application [13].
Here, we investigated the potential role of genetically CAR-modified NK-92 cells as a therapeutic
approach for PCa, the most common cancer among males in Europe and the USA [14–16]. The specific
targeting of this tumor by ACT represents a promising strategy to control the disease, as PCa expresses
distinct surface tumor-associated antigens that can be exploited for immune interventions. Among
these, the expression levels of the prostate-specific membrane antigen (PSMA) differentiate normal and
cancerous prostatic tissues, and parallel the Gleason score of PCa [17]. Interestingly, PSMA expression
also involves the neovasculature of several tumor entities, thus envisaging that the targeting of such
antigen could lead to an additional antiangiogenic effect not only in PCa but also in other cancer
histotypes. Therefore, PSMA appears a very promising target and indeed is currently exploited for
both imaging and therapeutic purposes [18]. It has been demonstrated that NK-92/CAR cells exhibit
appreciable anti-tumor activity in several clinical trials [13] against different hematological and solid
tumors. However, the use of NK-92/CAR cells in treating PCa has not yet been investigated. In this
novel approach, using a PSMA-specific CAR [19] to redirect NK-92 cells, we showed that genetically
modified NK-92/CAR cells acquired the ability to specifically and effectively lyse PSMA-expressing
PCa cells, in contrast to parental NK-92 cells. Furthermore, adoptive transfer of gene-modified NK-92
cells reduced tumor growth in different PCa mouse tumor models, and significantly enhanced survival.
In conclusion, our data pave the way to a new therapeutic perspective for PCa based on the
development of an off-the-shelf, renewable product that can be advanced as a reliable, efficient and
relatively low cost “universal” platform for adoptive cell therapy.
2. Materials and Methods
2.1. Cell Lines and Culture Conditions
LNCaP and PC3 (both human prostate carcinoma cell lines), 293T (human embryonic kidney cell
line), K562 (human myelogenous leukemia cell line), and NK-92 (human malignant non-Hodgkin’s
lymphoma natural killer cell line) were obtained from the American Type Culture Collection
(ATCC). PC3-PSMA, a PC3 derivative cell line stably expressing human PSMA, has been previously
described [20]. LNCaP, PC3, PC3-PSMA, and K562 were cultured in RPMI 1640 medium, while DMEM
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medium was used for 293T; all cell lines were enriched with 10% heat-inactivated fetal bovine serum
(FBS, Gibco). Firefly luciferase (fluc)-expressing PC3 and PC3-PSMA cell derivatives were obtained
by viral transduction as previously described [19]. NK-92 cells were grown in alpha MEM medium
supplemented with 12.5% horse serum and 12.5% FBS, and 200 IU/mL hIL-2 (Proleukin; Novartis
Pharma). All media were supplemented with 2 mM L-Glutamine, 100 U/mL penicillin, and 100 µg/mL
streptomycin (all from Lonza), and maintained at 37 ◦C in a humidified 5% CO2 incubator.
2.2. Generation of CAR-Expressing NK-92 Cells
The anti-PSMA CAR/eGFP lentiviral transfer vector (LV), and viral particle production in 293 T
cells have been previously described [19]. NK-92 cells were transduced with viral particles for 18 h
at 37 ◦C and 5% CO2 in the presence of protamine sulfate (40 ug/mL; Sigma-Aldrich) and hIL-2
(500 IU/mL). Thereafter, the cells were maintained in culture by supplying fresh complete medium
containing hIL-2 (200 IU/mL). Enrichment of CAR-expressing NK-92 cells was carried out by flow
cytometry cell sorting with Moflo Astrios (Beckman Coulter) based on eGFP expression intensity,
and the resulting population was referred to as NK-92/CAR cells.
2.3. Irradiation of NK-92 Cells
NK-92/CAR and parental NK-92 cells were collected by centrifugation, counted, washed,
resuspended in fresh growth medium, and irradiated with 5 or 10 Gy using a γ-ray irradiator
(Schering). For in vitro proliferation and cytotoxicity assays, cells were irradiated with 10 Gy, washed,
resuspended in fresh growth medium, and cultured for up to 8 days. Proliferation was analyzed by
counting viable cells at different time points using trypan blue exclusion. For in vivo experiments,
cells were irradiated with 10 Gy and used directly.
2.4. Antibodies
CAR-expressing cells were labeled with the anti-c-myc mAb (clone 9E10; Sigma-Aldrich) or the
isotype control (mouse IgG1; Southern Biotech), followed by a secondary antibody (PE-conjugated goat
anti-mouse IgG; Southern Biotech). Cell surface markers were labeled using PE-conjugated antibodies
to CD85j, NKG2D, CD158d, CD27, and with the relative isotype controls (BioLegend). Flow cytometry
analyses were conducted using a FACSCalibur flow cytometer and FlowJO software (BD Biosciences).
2.5. Cytokine Release Assay
IFN-γ production was assessed by an ELISA IFN-γ Screening Set (Thermo Scientific), according
to the manufacturer’s instructions. Briefly, 1 × 105 NK-92/CAR cells were seeded in triplicate together
with 1 × 105 target cells (PC3 or PC3-PSMA), in 96-well round bottom plates. Cytokine secretion was
measured after 12 h of incubation. Negative and positive controls were represented by NK-92/CAR
cells that remained unstimulated or were treated with 40 ng/mL of PMA and 4 mg/mL of ionomycin
(Sigma-Aldrich), respectively. Parental NK-92 was included for comparison. Supernatants were then
analyzed using a VICTOR X4 (PerkinElmer).
2.6. Degranulation Assay
Degranulation of NK-92/CAR and parental NK-92 cells was induced upon interaction with target
cells at 1:1 ratio for 5 h at 37 ◦C, and was assessed by measuring the surface expression of CD107a
with an APC-labelled anti-CD107a detection antibody (Biolegend). Effector cells stimulated with
PMA/ionomycin or kept without targets served as controls.
2.7. Cytotoxicity Assay
The cytotoxic activity of NK-92/CAR and parental NK-92 cells was assessed in a standard 4h
51Cr-release assay. In brief, effector cells were incubated with 2 × 103 51Cr-labeled PC3-PSMA, PC3,
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LNCaP, and K562 cells at various E/T ratios in triplicate wells of 96-well round-bottom plates, with or
without a NKG2D blocking antibody (clone 1D11; Biolegend). Antibody was added to the effector
cells at a concentration of 50 µg/mL, and incubated for 1 h at 37 ◦C prior to the addition of the
targets. The cytotoxic activity of NK-92/CAR and parental NK-92 cells was evaluated before and after
irradiation. The percentage of specific 51Cr release into the supernatant was assessed as previously
described [21].
2.8. In Vivo Studies
All in vivo experiments involved 6- to 8-week-old NOD/SCID common γ chain knockout (NSG;
Charles River) male mice, which were housed in our Specific Pathogen Free (SPF) animal facility.
Procedures involving animals and their care were in conformity with institutional guidelines that
comply with national and international laws and policies (D.L. 26/2014 and subsequent implementing
circulars), and the experimental protocol (Authorization n. 1143/2015-PR) was approved by the Italian
Ministry of Health. During in vivo experiments, animals in all experimental groups were examined
daily for a decrease in physical activity and other signs of disease; severely ill animals (weight loss
exceeding 15%, lethargy, ruffled hair, low temperature) were euthanized by carbon dioxide overdose.
Winn assay. Winn assay was performed by injecting mice subcutaneously (s.c.) with 5 × 106 PC3
or PC3-PSMA cells, mixed with either RPMI, NK-92/CAR or NK-92 cells (5 × 106/mouse; 6 mice/group).
Tumor volume was calculated according to the following equation: V (mm3) = (d2 * D)/2, where d (mm)
and D (mm) are the smallest and largest perpendicular tumor diameters, respectively, as assessed by
caliper measurement.
Systemic treatment of subcutaneous prostate tumors. To assess the therapeutic activity of systemically
administered NK-92/CAR cells in a subcutaneous prostate tumor model, mice were injected
s.c. with 5 × 106 PC3-PSMA cells and 4 days later started intravenous (i.v.) treatment with effector cells
(10 × 106/mouse; 6 mice/group); cell administration was repeated for 3 times at alternate days over a one
week interval. Specificity of NK-92/CAR cells was assessed in mice injected s.c. with 5 × 106 PC3 cells,
while tumor-bearing mice left untreated or receiving parental NK-92 served as further control groups.
Systemic treatment of orthotopic prostate tumors. The therapeutic impact of adoptively transferred
NK-92/CAR cells was also evaluated in an orthotopic prostate tumor model. Mice were injected with
2.5 × 105 bioluminescent PC3-PSMA or PC3 cells into the anterior prostatic lobe, and 2 days later
started treatments as reported above. Tumor engraftment and response to therapy were evaluated by
bioluminescence (BLI).
2.9. Statistics
Statistical analysis was performed by Student’s t test when only two value sets were compared.
One-way ANOVA was used when the data involved three groups. Mice survival was compared using
log-rank survival statistics. Histograms represent mean values ± standard deviation. In scatter-plot
graphs, symbols indicate different samples or assays, and horizontal bars represent means ± standard
deviation. p < 0.05, p < 0.01 or p < 0.001 were considered statistically significant and indicated by
*, ** or ***, respectively. Statistical analysis was performed using GraphPad Prism 7.0 software.
3. Results
3.1. PSMA-Targeted NK-92/CAR Cells Acquire Antigen-Specific Cytotoxic Activity
To express the anti-PSMA CAR, we used an LV carrying a bidirectional promoter that drives the
simultaneous expression of the CAR molecule, and the eGFP reporter gene (17). After generation of
lentiviral particles and transduction of NK-92 cells, the eGFP-expressing NK-92/CAR subset underwent
enrichment by flow cytometry sorting, leading to a virtually 100% CAR-positive cell population
(Figure 1A). As NK-92 cells are endowed with intrinsic killing activity against the NK-sensitive
K562 cell line, we initially compared the natural cytotoxicity of the parental and the transduced
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populations. Both NK-92 and NK-92/CAR cells disclosed a relevant and overlapping lysis against
K562 cells (Figure 1B), thus demonstrating that the transduction and selection procedures do not
impinge on the intrinsic properties of NK-92 cells. Next, we evaluated the lytic activity of the retargeted
NK-92/CAR cells towards different prostate tumor targets. NK-92/CAR cells showed, even at low
E/T ratios, an extremely high cytotoxicity to PC3 cells stably transfected and expressing PSMA at
high intensity, which instead turned out resistant to parental NK-92 cells (Figure 1B). Likewise and
more importantly, LNCaP cells, which naturally harbor the PSMA antigen, were selectively killed by
NK-92/CAR cells but not the parental NK-92 counterparts (Figure 1B). As further proof of specificity,
both NK-92/CAR and NK-92 cells failed to lyse PSMA-negative PC3 cells included as a control
(Figure 1B). Overall, data indicate that the PSMA-specific CAR is fully functional within NK-92 cells
and confers antigen-selective redirected and enhanced activity.
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CAR surface expression on a NK-92/CAR eGFP-based sorted and enriched population was 
determined by flow cytometry with an antibody to a Myc tag present in the CAR moiety [19]. Left 
and central panels, eGFP and c-myc expression in the sorted population, respectively (open areas); 
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Figure 1. Anti-PSMA (prostate-specific membrane antigen) CAR (chimeric antigen
receptors)-engineered NK-92 cells acquire high and specific cytotoxicity to antigen-expressing cancer
cells. (A) CAR surface expression on a NK-92/CAR eGFP-based sorted and enriched population was
determined by flow cytometry with an antibody to a Myc tag present in the CAR moiety [19]. Left and
central panels, eGFP and c-myc expression in the sorted population, respectively (open areas); parental
NK-92 cells for eGFP expression and an isotype antibody for c-myc analysis served as controls (shaded
areas). Right dot plot reports the events gated on total viable cells. (B) Cytotoxicity by NK-92/CAR
(open squares) was investigated in 51Cr-release assays using as targets PSMA-negative K562 and PC3
cells (upper panels), and PSMA-expressing LNCaP and PC3 (bottom panels) cells. Parental NK-92
cells were included for comparison (full circles). Results are reported as mean values ± SD (n = 3) at
different effector to target (E/T) ratios.
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3.2. Irradiation Is a Safe Measure to Prevent NK-92/CAR Cell Proliferation
In phase I clinical trials with untargeted NK-92 cells, a 10 Gy irradiation step of the
effector population prior to infusion had been included as a safety measure to prevent
permanent engraftment [9,11]. It is quite conceivable that similar safety measures are requested for the
clinical application of retargeted NK-92 cells. Hence, we decided to test the effects of γ-irradiation on
growth and phenotype of NK-92/CAR cells. After exposure to either 5 or 10 Gy γ-irradiation, further
replication was prevented and the number of viable NK-92/CAR cells gradually declined, with living
cells no longer detectable after 5–7 days (Figure 2A). Then, to investigate the effects of irradiation
on the NK-92/CAR cell phenotype, we evaluated the potential modulation of some activation and
inhibition receptors typical of NK-92 cells [22]. No difference in the expression of CD27, NKG2D,
CD158d or CD85 cell markers was noted between NK-92/CAR and parental NK-92 cells (Figure 2B),
thus demonstrating that γ-irradiation does not alter the phenotype of NK-92 cells.
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Figure 2. The irradiation of CAR-transduced or parental NK-92 cells fully blocks the proliferation
but not impinges on phenotype. (A) Viability of NK-92 (left panel) and NK-92/CAR (right panel)
cells undergoing or not γ-irradiation at 5 or 10 Gy. Proliferation was analyzed by counting viable
cells at the indicated time points using trypan blue exclusion. Results are reported as mean values
± SD of 3 independent experiments. (B) Surface expression of different NK (natural killer) cells’
activation/inhibition receptors (CD85j, NKG2D, CD158d, and CD27) after γ-irradiation was analyzed by
flow cytometry staining with appropriate antibodies. Solid lines refer to NK-92/CAR cells, while dotted
lines represent parental counterparts.
3.3. Irradiated NK-92/CAR Cells Undergo Degranulation and IFN-γ Release Upon Interaction with
PSMA-Expressing Targets
NK and cytotoxic T cell-mediated lysis upon recognition of target cells requires efficient triggering
of the effector cells, which ultimately culminates in the exocytosis of lytic granules. To investigate the
degranulation of irradiated NK-92/CAR and parental NK-92 cells upon interaction with target cells,
we measured the surface expression of the lysosomal-associated membrane protein LAMP-1 (CD107a).
While a non-specific stimulus represented by the combination of PMA and ionomycin triggered a
massive and fully overlapping degranulation in either populations, thus further stressing the concept
that neither CAR transduction nor irradiation impinge on NK-92 functionality, PC3 cells produced only
marginal effects in line with the low recognition of such targets that lack PSMA expression. Conversely,
when the PSMA-expressing PC3 variant was used, NK-92/CAR cells underwent a strong upregulation
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of CD107a expression that was however absent in parental NK-92 cells (Figure 3A). In parallel, we also
tested IFN-γ release by NK-92/CAR and NK-92 cells following target engagement. Results of this assay
fully mirrored those already obtained with CD107a expression analysis, as PMA/ionomycin massively
but non-specifically stimulated either effector populations, PC3 cells were negligibly recognized,
while only NK-92/CAR cells produced significant levels of IFN-γ upon interaction with PSMA+ targets
(Figure 3B). Overall, these data demonstrate that the anti-PSMA CAR is selectively activated by the
specific antigen, and that the resulting signaling chain correctly proceeds from the membrane up to the
nucleus even in irradiated cells.
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3.4. NK-92/CAR Cells Retain a High and Specific Target Killing Activity upon Irradiation
To assess the effects of irradiation on cytotoxic activity, NK-92/CAR cells were irradiated at 10 Gy
and then co-incubated for 4 h with target cells. Similarly treated NK-92 parental cells were used
as a control. In spite of irradiation, NK-92/CAR cells disclosed a higher cytotoxicity than NK-92
counterparts towards PSMA-expressing PC3 (p = 0.0012) and LnCaP (p < 0.0001) targets (Figure 4A).
Again, this increased lytic activity was strictly antigen-specific, as NK-92/CAR and parental NK-92 cells
mediated low and comparable killing of PSMA-negative PC3 targets, while irradiation did not interfere
with the intrinsic NK-like activity of either effectors since K562 targets were lysed at comparable levels.
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Figure 4. Lytic activity of irradiated NK-92/CAR cells before and after NKG2D blocking. (A) Cytotoxicity
of 10 Gy-irradiated NK-92/CAR (open squares) and NK-92 (filled circles) cells was investigated against
K562, PC3, LNCaP, and PC3-PSMA cells, at different E/T ratios. (B) To evaluate the effects of NKG2D
blocking, irradiated NK-92/CAR (open squares) and parental NK-92 (filled squares) cells were pre-treated
with anti-NKG2D antibody for 1 h before incubation with K562, PC3, LNCaP, and PC3-PSMA targets.
Irradiated non-blocked CAR-transduced (open circles) and wild-type (filled circles) effectors were
included for comparison. Lysis data are shown as mean values ± SD of 3 independent experiments.
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3.5. CAR-Mediated Cytotoxicity is Independent of NKG2D Activity in NK-92/CAR Cells
NKG2D is considered the main receptor involved in NK-92 lytic activity. To further confirm that
the increased killing of NK-92/CAR cells was strictly PSMA antigen-specific and could be ascribed only
to CAR activation, we analyzed the impact of NKG2D inhibition on cytotoxicity of irradiated effectors
(Figure 4B). Upon NKG2D blocking, NK-92/CAR cells continued to show an elevated cytotoxic activity
against PSMA-expressing targets, and the percentages of lysis remained essentially similar to those
detected in the absence of blocking. On the other hand, NKG2D inhibition almost completely shut off
the intrinsic lytic activity of both NK-92/CAR and NK-92 parental cells, thus suggesting that CAR- and
NKG2D-mediated pathways act independently and do not interfere with each other.
3.6. NK-92/CAR Cells Control the Growth of Locally Implanted Prostate Carcinoma
The in vivo therapeutic efficacy of irradiated NK-92/CAR cells was initially evaluated using a Winn
assay (Figure 5A). When NK-92/CAR effectors were co-injected s.c. with PC3-PSMA cells, tumor growth
was completely blocked and no neoplastic mass developed. Conversely, co-administration of parental
NK-92 cells led to only a slight but not significant delay of the tumor growth, which ultimately
reached values observed in untreated animals (Figure 5A, left panel). Notably, transfer of either
retargeted or parental NK-92 cells did not significantly impact on the progression of PSMA-negative
PC3 tumors (Figure 5A, right panel), thus reinforcing the concept that the effects observed against
antigen-expressing prostate cancer were strictly CAR-dependent. Since the Winn assay does not
recapitulate a real therapeutic setting, we moved to assess the antineoplastic activity of NK-92/CAR
cells against established tumors (Figure 5B). To this end, NSG mice were injected s.c. with PC3-PSMA
cells and, when tumors became palpable, received systemic injections of NK-92/CAR or parental NK-92
irradiated effectors. While progressive tumor growth was observed in both untreated control mice
and those receiving parental NK-92 cells, injections of NK-92/CAR effectors strongly affected prostate
carcinoma development, an effect that involved all treated animals (Figure 5B, left panel). Furthermore,
in this experimental setting, neither the treatment with NK-92/CAR cells nor the parental counterparts
restrained the growth of PC3 tumors that lack PSMA (Figure 5B, right panel). Overall, data indicate
that irradiated NK-92/CAR cells are capable of penetrating tissues and reaching distant tumor sites,
where they exert antigen-specific therapeutic activities.
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inoculated .c. in NSG ( OD/SCID common γ chain knockout) mice alone (filled tri ngles), or mixed
with NK-92/CAR (filled squares) or parental NK-92 (fill d circles) cells. Tumor growth was monitored
ver time by caliper measurement (6 mice/group). (B) Therapeutic activity against established tumors.
NK-92/CAR cells or untransduced counterparts were administ red i.v. in NSG mice for 3 tim s at
alternate days, starting 4 days after s.c. injection of PC3-PSMA (left panel) or PC3 (right panel) tumor
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3.7. The Adoptive Transfer of NK-92/CAR Cells Is Therapeutic in an Orthotopic and Metastatic Prostate
Tumor Model
Heterotopic tumor models may always raise concer s about the real tr nslation to clinics.
The efore, we decided to assess the therapeutic potential of irradiated and adoptively transferred
NK-92/CAR cells in an orthotopic prostate tumor model that would better resemble the clinical setting.
Bioluminescent PC3-PSMA prostate tumor cells were implanted into the anterior prostatic lobe of male
NSG mice, followed by i.v. injections of parental NK-92 or retargeted NK-92/CAR-irradiated effectors;
treatments were carried out at days 2, 5, and 8 after tumor implant, and then thrice per week for a
month (Figure 6A). In control mice that received PBS only, prostate cancer developed progressively,
leading in about a month to massive peritoneal metastasis. The administration of unmodified NK-92
cells was followed by a modest but significant tumor growth reduction, while only NK-92/CAR cells
dramatically halted carcinoma progression as demonstrated by the significant reduction of emitted
photons at day 28 (NK-92/CAR vs. NK-92, p = 0.005; NK-92/CAR vs. Controls, p < 0.0001; NK-92 vs.
Controls p = 0.0142) (Figure 6B,C). More importantly, the transfer of NK-92/CAR cells significantly
improved survival of treated mice in comparison to untreated animals (median survival 27 days,
p = 0.0018) or animals receiving parental NK-92 (median survival 33.5 days, p = 0.0048) (Figure 6D),
with 66% of mice still alive at the endpoint of the experiment. On the whole, these data demonstrate
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that NK-92/CAR cells are endowed with high and specific antitumor activity against PSMA-expressing
prostate cancer cells, and that their viability and functionality is transiently preserved after γ-irradiation
at a dose that prevents further effector cell replication but still permits target cell recognition and
therapeutic activity in vivo.
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Figure 6. Antitumor activity of NK-92/CAR cells against orthotopic PC3-PSMA xenografts. (A)
Representative schedule of the experiment. Luciferase-expressing PC3-PSMA cells were injected into
the anterior prostatic lobe of NSG mice. Starting from two days later, mice received i.v. injections of
NK-92/CAR or parental NK-92 cells thrice per week for 4 weeks. C ntr l mice were treated with PBS,
and tumo growth was monitored by BLI. (B) Representativ imag of mice from experimental groups
(one mouse/gr up) at day 28. (C) Graph reports cumulative results of the regions of interest (ROI)
in total body. Tumor grow h was monitored as total flux (ph/sec). Graphs show mean ± SD of three
independent expe iments. (D) Cumulative Kaplan–Meie survival curves of NSG mice (untreated
mice, black line; NK-92 treated mice, red line; NK-92/CAR treated ice, blue line). * p < 0.05, ** p < 0.01
and *** p < 0.001.
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4. Discussion
Undoubtedly, cancer immunotherapy is in an exciting period due to the remarkable successes
achieved with the introduction of checkpoint inhibitors [23–27] and CAR-T cells, at least in patients with
lymphoid malignancies [1–3]. The latter, in particular, strongly underline the concept that immune cells
can be converted into powerful therapeutic agents. Nonetheless, CAR-T cell treatment is associated
with heavy adverse events in a significant number of patients and, additionally, the logistics and costs
of such an approach pose significant challenges for making it available to a large number of potentially
suitable recipients.
NK cells may represent safer effectors than T cells for cancer therapy. However, even in this
case there are biological, logistical, and financial constrains for the application of blood NK cells as a
treatment modality for cancer patients. Autologous NK cells are typically not very effective, as they are
functionally silenced when encountering self-MHC antigens, and can be also frequently compromised
by the underlying disease and its treatment. Indeed, NK cell function can be impaired in patients with
malignant disorders, resulting in a reduced proliferative response and cytotoxic activity [28].
In this context, clinically applicable human cell lines, such as NK-92, may provide a valuable
alternative. NK-92 cells proliferate and expand easily in culture with a doubling time of 2-4 days,
and are the only cell line that is consistently and highly cytotoxic to cancer targets. This cell line
has undergone an extensive preclinical assessment [29–32] and has been tested in clinical trials [9,11]
that overall demonstrated the lack of infusion-associated toxicities in cancer patients. Due to the
safety of infusion and feasibility of large-scale expansion, NK-92 cells are considered a promising
cellular tool for ACT. Furthermore, genetic modification of NK-92 cells with CARs may lead to targeted
cancer therapies, which are expected to be more specific and efficient. This latter concept has found
a preclinical validation in different experimental cancer models. Indeed, NK-92 engineering with
CARs to CD19/CD20 or disialoganglioside GD2, HER2 receptor tyrosine kinase, and epidermal growth
factor receptor EGFR, disclosed higher activity against hematological malignancies [31,33,34] or solid
tumors [7,35–37]. Nonetheless, the present study is the first to investigate the use of CAR-modified
NK-92 cells against PCa; in particular, we aimed at modifying NK-92 cells to express a PSMA-specific
CAR, and thus to convert them into a prostate cancer-specific therapeutic tool characterized by
improved efficacy. In the case of the castration-resistant PCa and in its metastatic form, actually
no curative interventions are available. Therefore, the main goal is to tackle the growth of the
castration-resistant PCa and the metastatic disease.
In fact, we showed that CAR engineering endows NK-92 cells with PSMA-specific recognition
capacity, and strongly enhances their lytic activity against relevant targets without interfering with
the inherent NK-like activity. Since such characteristics are maintained after irradiation, this may be
relevant for future clinical application of NK-92/CAR cells, where irradiation may be included as a
safety measure as reported in previous phase I clinical trials with untargeted NK-92 counterparts [8–11].
Although information about the clinical application of irradiated NK-92/CAR cells is still scarce [38],
such a concept seems supported by data from a recent clinical trial in relapsed and refractory acute
myeloid leukemia [39] and in several other early phase clinical trials with CAR-engineered NK-92
cells that are presently ongoing in Europe, China, and the US. Regarding glioblastoma (GB), where
patients’ median survival remains less than 1 year, despite multimodal regimes, a phase I clinical trial
“Intracranial Injection of NK-92/5.28.z Cells in Patients With Recurrent HER2-positive Glioblastoma”
(i.e., CAR2BRAIN, NCT03383978, clinicaltriaols.gov) was started in 2017, in order to evaluate the
feasibility, safety and tolerability of the direct injection of irradiated NK-92 CAR-recognizing ErbB2
antigen into the wall of the resection cavity [40]. In this case the local therapy approach was chosen to
increase the accumulation of the engineered cells at the site of the lesion overcoming the problems
associated with the blood–brain barrier passage.
Two additional aspects are noteworthy: first, the full functionality of the CAR not only confers
antigen-specific and increased lytic activity but also leads to significant IFN-γ secretion. This is typical
for activated NK cells, and could in principle result in recruitment and maturation of antigen-presenting
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cells, and enhancement of endogenous antitumor immune responses in an immunocompetent host [41].
Second, NK-92 cells can spontaneously kill tumors by recognizing diverse ligands via a variety
of NK activating receptors. Among these, the NKG2D receptor is one of the major signaling
pathways involved in cancer immunosurveillance [41–44]. As we demonstrated that CAR- and
NKG2D-dependent activation pathways do not reciprocally interfere, it is conceivable that they can act
in concert in engineered NK-92 cells to potentiate tumor destruction.
A final point deserves attention. Upon in vivo transfer, irradiated NK-92/CAR cells retain target
cell specificity and therapeutic activity. Currently, irradiation of the cells before in vivo application
is the usual safety method employed in the clinical setting [9,11] to block proliferation and prevent
permanent engraftment of NK-92 cells. While this approach has minimal effects on their short-term
functionality, it negatively impacts on their in vivo persistence and long-term antitumor efficacy.
Hence, repeated infusions of irradiated NK-92 cells are required as a means to circumvent their limited
survival, but the approach has drawbacks in terms of costs and patient compliance. In this regard,
introducing a suicide gene into NK-92/CAR cells might represent a valid safety option alternative to
irradiation, because it would likely allow a single administration of effectors that are subsequently
amenable to being completely switched off after exerting their therapeutic activity or in the case of
severe, unwanted toxicity [42–47].
5. Conclusions
Overall, the results of this study highlight the potentialities of PSMA-specific CAR-modified
NK-92 cells as a novel and exciting perspective for prostate cancer adoptive immunotherapy. Moreover,
the potent antitumor activity, the immediate availability as a fully defined and characterized cell
product, and the lack of obvious risks of manufacturing failures suggest that these cells can be advanced
as a valid and cost-effective alternative to CAR-modified T cells. Finally, the robust ex vivo expansion of
NK-92 cells to high numbers and their exquisite safety profile, as well as the ease of genetic modification,
make this cell line an ideal platform for the development of off-the-shelf therapeutic CAR-engineered
variants to target other solid tumors.
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